These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28479139)

  • 1. From CLSI to EUCAST guidelines in the interpretation of antimicrobial susceptibility: What is the effect in our setting?
    Sánchez-Bautista A; Coy J; García-Shimizu P; Rodríguez JC
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Apr; 36(4):229-232. PubMed ID: 28479139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.
    Hombach M; Bloemberg GV; Böttger EC
    J Antimicrob Chemother; 2012 Mar; 67(3):622-32. PubMed ID: 22167240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
    Süzük S; Kaşkatepe B; Avcıküçük H; Aksaray S; Başustaoğlu A
    Mikrobiyol Bul; 2015 Oct; 49(4):494-501. PubMed ID: 26649407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms.
    Wolfensberger A; Sax H; Weber R; Zbinden R; Kuster SP; Hombach M
    PLoS One; 2013; 8(11):e79130. PubMed ID: 24223893
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Fleischmann WA; Greenwood-Quaintance KE; Patel R
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
    Jones RN; Wilson ML; Weinstein MP; Stilwell MG; Mendes RE
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms.
    Giani T; Morosini MI; D'Andrea MM; García-Castillo M; Rossolini GM; Cantón R
    Clin Microbiol Infect; 2012 Nov; 18(11):E452-8. PubMed ID: 22909279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement.
    Gaur P; Hada V; Rath RS; Mohanty A; Singh P; Rukadikar A
    Cureus; 2023 Mar; 15(3):e36977. PubMed ID: 37139290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimicrobial Susceptibility of Pathogenic Gram-positive Anaerobic Cocci: Data of a University Hospital in Turkey].
    Akgül Ö; Söyletir G; Ülger Toprak N
    Mikrobiyol Bul; 2020 Jul; 54(3):404-417. PubMed ID: 32755517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?
    Marchese A; Esposito S; Barbieri R; Bassetti M; Debbia E
    BMC Infect Dis; 2012 Aug; 12():181. PubMed ID: 22866984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey.
    Soyletir G; Altinkanat G; Gur D; Altun B; Tunger A; Aydemir S; Kayacan C; Aktas Z; Gunaydin M; Karadag A; Gorur H; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i71-83. PubMed ID: 27048584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption.
    Stokkou S; Tammer I; Zibolka S; Grabau C; Geginat G
    BMC Res Notes; 2014 Sep; 7():603. PubMed ID: 25185565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study.
    Fernández-Cuenca F; López-Hernández I; Cercenado E; Conejo C; Tormo N; Gimeno C; Pascual A
    J Antimicrob Chemother; 2021 Apr; 76(5):1187-1196. PubMed ID: 33555012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.